Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872432 | 0.95 | GPR119 (0.59) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL387467 | 0.91 | GPR119 (0.53) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL387359 | 0.88 | GPR119 (0.57) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL387215 | 0.85 | GPR119 (0.57) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL387344 | 0.83 | GPR119 (0.58) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL387207 | 0.82 | GPR119 (0.66) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL388814 | 0.81 | GPR119 (0.57) | GPR119GPR183KCNH2 | |
| Trifluoroacetic Acid SCHEMBL387475 | 0.81 | GPR119 (0.55) | GPR119GPR183KCNH2 | |
| Trifluoroacetic Acid SCHEMBL388420 | 0.80 | GPR119 (0.56) | GPR119GPR183KCNH2 | |
| Trifluoroacetic Acid SCHEMBL384442 | 0.80 | GPR119 (0.56) | GPR119GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885KCNH2 2919/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885KCNH2 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.